logo
Search…
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Search...
search
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Home > Latest

Hengrui Pharmaceuticals (01276.HK) spent RMB 8.9971 million to repurchase 195,000 A shares on October 16.

date
16/10/2026
Zhitong Finance APP news: Hengrui Pharmaceuticals (01276.HK) announced that on October 16, 2026, it spent RMB 8.9971 million to repurchase 195,000 A shares.
Latest
1 m ago
China Broadcasting Data (00471.HK): Hearing of Petition 1 adjourned to November 2
3 m ago
Lianmei Holdings (600167.SH) and related shareholders received a case filing notice from the China Securities Regulatory Commission.
4 m ago
Zhaoke Ophthalmology-B (06622.HK) repurchased 4,500 shares on October 16 for HK$9,172.35.
4 m ago
AInnovation (02121.HK) repurchased 520,200 shares for HKD 1,899,300 on October 16.
4 m ago
K W NELSON GP (08411) subsidiary awarded a contract to provide design and fitting-out works in Hong Kong
See all latestmore
logo
Contact US
qr
+852 - 60190728
[email protected]
Customer Support
About Us
Contact Us
Frequently Asked
Privacy Policy
Terms of Use
Commercial Services
Advertising
Business Development
Copyright
Terms of Service
©️2013 - 2026 GMT EIGHT Holdings. All Rights Reserved.